298 related articles for article (PubMed ID: 26569500)
1. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
Yonesaka K; Takegawa N; Satoh T; Ueda H; Yoshida T; Takeda M; Shimizu T; Chiba Y; Okamoto I; Nishio K; Tamura T; Nakagawa K
PLoS One; 2015; 10(11):e0143132. PubMed ID: 26569500
[TBL] [Abstract][Full Text] [Related]
2. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
3. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
Kogawa T; Doi A; Shimokawa M; Fouad TM; Osuga T; Tamura F; Mizushima T; Kimura T; Abe S; Ihara H; Kukitsu T; Sumiyoshi T; Yoshizaki N; Hirayama M; Sasaki T; Kawarada Y; Kitashiro S; Okushiba S; Kondo H; Tsuji Y
Target Oncol; 2015 Mar; 10(1):125-33. PubMed ID: 24859798
[TBL] [Abstract][Full Text] [Related]
4. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer.
Klupp F; Sass M; Bergmann F; Khajeh E; Ghamarnejad O; Hassenpflug M; Mehrabi A; Kulu Y
Oncol Lett; 2021 Jun; 21(6):448. PubMed ID: 33868486
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum interleukin-17 levels in colorectal cancer patients.
Karabulut S; Usul Afsar C; Karabulut M; Kilic L; Alis H; Kones O; Bilgin E; Faruk Aykan N
J BUON; 2016; 21(5):1137-1145. PubMed ID: 27837615
[TBL] [Abstract][Full Text] [Related]
6. Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3
Benkhelifa S; Rafa H; Belhadef S; Ait-Kaci H; Medjeber O; Belkhelfa M; Hetit S; Ait-Younes S; De Launoit Y; Moralès O; Mahfouf H; Delhem N; Touil-Boukoffa C
Inflammopharmacology; 2019 Aug; 27(4):685-700. PubMed ID: 30680650
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer.
Li Y; Wang B; Yang W; Ma F; Zou J; Li K; Tan S; Feng J; Wang Y; Qin Z; Chen Z; Ding C
Nat Commun; 2024 Feb; 15(1):980. PubMed ID: 38302471
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin as a Novel Serum Marker of Puberty in Girls.
Biro FM; Pinney SM; Schwartz RC; Huang B; Cattran AM; Haslam SZ
J Pediatr Adolesc Gynecol; 2017 Oct; 30(5):535-539. PubMed ID: 28216130
[TBL] [Abstract][Full Text] [Related]
9. Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies.
Li Y; Wang B; Ma F; Jiang D; Wang Y; Li K; Tan S; Feng J; Wang Y; Qin Z; Xu G; Tian S; Zhang X; Xu C; Wu J; Xu J; Hou Y; Ding C
Cell Rep Med; 2023 Dec; 4(12):101311. PubMed ID: 38086380
[TBL] [Abstract][Full Text] [Related]
10. 3D stochastic microsensors for molecular recognition and determination of heregulin-α in biological samples.
Stefan-van Staden RI; Negut CC; Gheorghe SS; Ciorîță A
Anal Bioanal Chem; 2021 May; 413(13):3487-3492. PubMed ID: 33763747
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls.
Peterson EA; Pectasides E; Shabbeer S; Wiechmann L; Sparano JA; Kenny PA
Exp Hematol Oncol; 2013 Sep; 2(1):25. PubMed ID: 24010672
[TBL] [Abstract][Full Text] [Related]
12. Resistance to EGFR-targeted therapy: a family affair.
Vlacich G; Coffey RJ
Cancer Cell; 2011 Oct; 20(4):423-5. PubMed ID: 22014569
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
Tarazona N; Cervantes A
Ann Oncol; 2018 Jan; 29(1):7-8. PubMed ID: 29045545
[No Abstract] [Full Text] [Related]
14. Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
Buta C; Benabou E; Lequoy M; Régnault H; Wendum D; Merabtene F; Chettouh H; Aoudjehane L; Conti F; Chrétien Y; Scatton O; Rosmorduc O; Praz F; Fartoux L; Desbois-Mouthon C
J Exp Clin Cancer Res; 2016 Sep; 35(1):154. PubMed ID: 27680564
[No Abstract] [Full Text] [Related]
15. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
16. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao HW; Hsu JM; Xia W; Wang HL; Wang YN; Chang WC; Arold ST; Chou CK; Tsou PH; Yamaguchi H; Fang YF; Lee HJ; Lee HH; Tai SK; Yang MH; Morelli MP; Sen M; Ladbury JE; Chen CH; Grandis JR; Kopetz S; Hung MC
J Clin Invest; 2015 Dec; 125(12):4529-43. PubMed ID: 26571401
[TBL] [Abstract][Full Text] [Related]
17. Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function.
Epstein DM; Buck E
J Clin Invest; 2015 Dec; 125(12):4320-2. PubMed ID: 26571394
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
Lo L; Patel D; Townsend AR; Price TJ
Expert Opin Drug Metab Toxicol; 2015; 11(12):1907-24. PubMed ID: 26572750
[TBL] [Abstract][Full Text] [Related]
19. Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma.
Cheng L; Xia Z; Bian X; Li G; Hu J; Cao Y; Wang Q; Qian X
Onco Targets Ther; 2015; 8():3185-92. PubMed ID: 26586952
[TBL] [Abstract][Full Text] [Related]
20. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
